Pacira Pharmaceuticals, Inc.

Clinical trials sponsored by Pacira Pharmaceuticals, Inc., explained in plain language.

Pacira Pharmaceuticals, Inc. PCRX NASDAQ

A pharmaceutical company focused on non-opioid pain management therapies.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Could a freezing device loosen stiff muscles? new trial begins Results expected Oct 2026 (estimated)
One-Shot gene therapy could ease knee arthritis pain for years Results expected Nov 2026 (estimated)
New shot aims to ease shoulder arthritis pain Results expected Dec 2026 (estimated) 🚀 Make-or-break
New pain relief for tiny hearts: study tests EXPAREL in kids under 6 Results expected Jan 2027 (estimated)

Browse trials soon ready across all sponsors →

Trials to join now! 3 Not yet finished but already full! 3 Terminated 1

New hip injection method tested for arthritis pain

Symptom relief Stopped early

This study tested a new way to inject the drug ZILRETTA into the hip joint for people with hip osteoarthritis. The goal was to see if using different needle sizes could improve the success rate of the injection. Only one person took part before the study was stopped early.

Phase 2 • Sponsor: Pacira Pharmaceuticals, Inc • Aim: Symptom relief

Last updated Jun 27, 2026 08:06 UTC

Pacira Pharmaceuticals, Inc.

Upcoming readouts

New hip injection method tested for arthritis pain